Skip to main content
. Author manuscript; available in PMC: 2019 Jun 7.
Published in final edited form as: Curr Protoc Pharmacol. 2018 Jun 7;81(1):e41. doi: 10.1002/cpph.41

Table 2.

HDAC inhibitor compounds and their reported IC50 (nM). Hull et al., 2016; Beckers et al., 2007; Selleckchem.com

HDACi HDAC1 HDAC2 HDAC3 HDAC8 HDAC4 HDAC6 HDAC7 HDAC9 Broad Spectrum
TSA 2±0 3±0 4±1 456±59 6±2 3±1 5±2 6±5 1.8
Vorinostat (SAHA) 68±14; 21±13; 10 164±45 48±17; 37±11; 20 1524±463; 1200±380 101±31 90±26; 25±6 104±35 107±21 10
Entinostat (MS275) 181±62; 180±70 1155±134 2311±803; 740±250; 1700 44900±18100 >10,000 HDAC4, 6, 7, 8, 9
Romidepsin (FK228) 1.6 ; 36 3.9 ; 47
Mocetinostat (MGCD0103) 34±17 ; 820±1.4 ; 150 34±8 ; 290 998±431 ; 620±160 ; 1660 >10,000 HDAC4, 6, 7, 8, 9; 590 HDAC11;
Panobinostat (LBH589) 3±0 3±0 4±1 12±5 61±1 14±7 3±2 5-20
Belinostat 41±6 125±21 30±0 216±43 115±16 82±19 67±22 128±46 27
Apicidin 0.299 120±28 43±7 575±111
Valproic acid 171000 ; 400000
Dacinostat (LAQ824) 1.8±0.6 3.7±3 140±34 15±7 32
Sodium Butyrate 175000 ; 300000 400000 300000